MSCs associated with multiple myeloma exhibit diminished osteogenic differentiation, elevated secretion of IL-6 and CCL2, and increased facilitation of myeloma cell proliferation and drug resistance. This evidence concerns the gene IL6 and plasma cell myeloma.